Exploring the therapeutic potential of ADC combination for triple-negative breast cancer

Abstract

Abstract Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Standard treatment options for TNBC mainly involve surgery, radiation treatment, and chemotherapy. Such treatment, however, are linked to a high risk of relapses both locally and systemically. Antibody-drug conjugates (ADCs) have recently arisen as a useful and promising option for cancer treatment. ADCs, referred to as "biological missiles", are composed of monoclonal antibodies (mAbs) that target the tumor antigens and deliver anticancer drugs as a payload. As of right now, several ADCs are undergoing clinical research around the world, including sacituzumab govitecan (SG) approved recently by the FDA for the treatment of TNBC. Due to the fact that only a small proportion of patients with TNBC respond to ADC therapy, and that drug resistance often occurs, growing evidence supports combination strategies using ADCs to treat TNBC. Herein, we described the current utilization of ADCs and discussed the prospect of combining ADCs with other therapies for treating TNBC.